SLA Pharma AG are meeting with the FDA in October 2019 to discuss a new drug application for our late stage development ALFA™ for the treatment of familial adenomatous polyposis (FAP). ALFA™ is currently undergoing clinical studies in Europe, and we are excited that a positive outcome from this FDA meeting will help bring ALFA™ to the US market.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published.